ECSP067056A - Anticuerpos - Google Patents

Anticuerpos

Info

Publication number
ECSP067056A
ECSP067056A EC2006007056A ECSP067056A ECSP067056A EC SP067056 A ECSP067056 A EC SP067056A EC 2006007056 A EC2006007056 A EC 2006007056A EC SP067056 A ECSP067056 A EC SP067056A EC SP067056 A ECSP067056 A EC SP067056A
Authority
EC
Ecuador
Prior art keywords
antibodies
psgl
selectin
glycoprotein
ligand
Prior art date
Application number
EC2006007056A
Other languages
English (en)
Inventor
Rong-Hwa Lin
Chung Nan Chang
Pei-Jiun Chen
Chiu-Chen Huang
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35394680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP067056(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of ECSP067056A publication Critical patent/ECSP067056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención se relaciona con anticuerpos y sus derivados que inducen apoptosis al fijarse a Ligando-1 Glicoproteína 1P-Selectina (PSGL-1) sobre células-T activadas.
EC2006007056A 2004-05-10 2006-12-08 Anticuerpos ECSP067056A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10

Publications (1)

Publication Number Publication Date
ECSP067056A true ECSP067056A (es) 2007-01-26

Family

ID=35394680

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007056A ECSP067056A (es) 2004-05-10 2006-12-08 Anticuerpos

Country Status (28)

Country Link
US (8) US7604800B2 (es)
EP (3) EP1765396B1 (es)
JP (4) JP5623690B2 (es)
KR (1) KR101256400B1 (es)
CN (2) CN103980361B (es)
AR (1) AR048781A1 (es)
AU (1) AU2005244072C1 (es)
BR (1) BRPI0510567B8 (es)
CA (3) CA2566305C (es)
DK (1) DK1765396T3 (es)
EC (1) ECSP067056A (es)
EG (1) EG26781A (es)
ES (3) ES2448468T3 (es)
HK (1) HK1102760A1 (es)
IL (3) IL178838A (es)
MX (1) MXPA06012986A (es)
MY (1) MY148646A (es)
NO (1) NO341844B1 (es)
NZ (3) NZ590690A (es)
PH (1) PH12015500247A1 (es)
PL (1) PL1765396T3 (es)
PT (1) PT1765396E (es)
RU (1) RU2482131C2 (es)
SG (2) SG10201606541UA (es)
TW (2) TWI448474B (es)
UA (1) UA100356C2 (es)
UY (1) UY28886A1 (es)
WO (1) WO2005110475A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
NZ551625A (en) * 2004-05-11 2011-03-31 Abgenomics Cooperatief Ua T-cell death-inducing epitopes
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
EP2351777B1 (en) * 2008-10-28 2015-10-28 Shionogi&Co., Ltd. Anti-muc1 antibody
TWI633605B (zh) * 2008-10-31 2018-08-21 半導體能源研究所股份有限公司 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme ANTI-GITRANT ANTIBODIES
US8889132B2 (en) * 2010-06-30 2014-11-18 Mount Sinai Hospital Antibodies against human HIF-1α
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
WO2012174001A1 (en) * 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
EP2769223A1 (en) 2011-10-17 2014-08-27 Westfälische Wilhelms-Universität Münster Assessment of pml risk and methods based thereon
PT2888283T (pt) 2012-08-24 2018-11-16 Univ California Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases
TWI660972B (zh) * 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
EP3334453A4 (en) * 2015-08-13 2019-02-06 New York University SPECIFIC ANTIBODY MOLECULES OF THE ASP421 EPITOPE TRUNCATED FROM THE TAU PROTEIN AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY
BR112018013912A2 (pt) * 2016-01-08 2018-12-18 Bioalliance C.V. anticorpos tetravalentes anti-psgl-1 e usos dos mesmos
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
US11306150B2 (en) 2017-01-11 2022-04-19 Bristol-Myers Squibb Company Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
CN110740749A (zh) 2017-03-14 2020-01-31 戊瑞治疗有限公司 在酸性pH下与VISTA结合的抗体
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
TW202110891A (zh) * 2019-06-04 2021-03-16 美商維西歐製藥公司 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
MX2022009044A (es) * 2020-01-22 2022-08-11 Shanghai Senhui Medicine Co Ltd Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
AU2022394559A1 (en) * 2021-11-17 2024-05-09 Altrubio Inc. Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
CA2130173A1 (en) * 1992-03-17 1993-09-30 Norman Hardman Genetically engineered antibodies
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
JPH08503617A (ja) * 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
AU694933B2 (en) * 1993-01-25 1998-08-06 Dana-Farber Cancer Institute, Inc. Chimeric L- and P-selectin by exchange of domains - uses thereof
NZ266934A (en) * 1993-05-04 1997-07-27 Cytel Corp Blocking p-selectin antibody and compositions thereof
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
AU723262B2 (en) 1995-08-03 2000-08-24 Board Of Regents Of The University Of Oklahoma, The Peptide and O-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
JP2002528513A (ja) 1998-10-30 2002-09-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｐ−セレクチンリガンド（ｐｓｇｌ）アンタゴニストによる細胞毒性ｔ−細胞分化の阻害
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
WO2001089564A2 (en) * 2000-05-19 2001-11-29 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
CN1124928C (zh) * 2000-07-11 2003-10-22 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2433225A1 (en) 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
NZ551625A (en) 2004-05-11 2011-03-31 Abgenomics Cooperatief Ua T-cell death-inducing epitopes
WO2012174001A1 (en) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof

Also Published As

Publication number Publication date
MXPA06012986A (es) 2007-02-12
AU2005244072B2 (en) 2012-05-31
CA2907141C (en) 2016-05-31
TWI402274B (zh) 2013-07-21
US20130101587A1 (en) 2013-04-25
WO2005110475A2 (en) 2005-11-24
BRPI0510567B1 (pt) 2018-11-13
US20050266003A1 (en) 2005-12-01
TW201313740A (zh) 2013-04-01
EP2377889A3 (en) 2012-03-28
JP5623690B2 (ja) 2014-11-12
TW200536860A (en) 2005-11-16
BRPI0510567B8 (pt) 2021-05-25
US20150183870A1 (en) 2015-07-02
DK1765396T3 (en) 2014-02-24
EP1765396A2 (en) 2007-03-28
ES2602633T3 (es) 2017-02-21
CA2907141A1 (en) 2005-11-24
AU2005244072A1 (en) 2005-11-24
EP1765396B1 (en) 2013-11-20
CN103980361B (zh) 2017-06-23
NZ590690A (en) 2012-10-26
CA2812040C (en) 2016-05-03
WO2005110475A3 (en) 2006-02-23
US8361472B2 (en) 2013-01-29
NZ551626A (en) 2010-03-26
US9631019B2 (en) 2017-04-25
CA2812040A1 (en) 2005-11-24
MY148646A (en) 2013-05-15
RU2006143686A (ru) 2008-06-20
US8287871B2 (en) 2012-10-16
CN1984680A (zh) 2007-06-20
CN103980361A (zh) 2014-08-13
IL178838A0 (en) 2007-03-08
JP2011200247A (ja) 2011-10-13
PT1765396E (pt) 2014-02-25
EP2377890A2 (en) 2011-10-19
US20110172397A1 (en) 2011-07-14
EP2377889B1 (en) 2016-07-13
US7604800B2 (en) 2009-10-20
EG26781A (en) 2014-09-07
SG10201606541UA (en) 2016-09-29
UA100356C2 (ru) 2012-12-25
PL1765396T3 (pl) 2014-07-31
BRPI0510567A (pt) 2007-11-20
KR20070020048A (ko) 2007-02-16
CN1984680B (zh) 2014-11-05
AR048781A1 (es) 2006-05-24
US20130102762A1 (en) 2013-04-25
EP2377890A3 (en) 2011-12-28
AU2005244072C1 (en) 2012-09-20
US20090191204A1 (en) 2009-07-30
JP2014223084A (ja) 2014-12-04
NO341844B1 (no) 2018-02-05
KR101256400B1 (ko) 2013-04-26
TWI448474B (zh) 2014-08-11
CA2566305C (en) 2014-10-14
ES2448468T3 (es) 2014-03-14
PH12015500247A1 (en) 2015-12-14
EP2377889A2 (en) 2011-10-19
CA2566305A1 (en) 2005-11-24
ES2598034T3 (es) 2017-01-24
US8663641B2 (en) 2014-03-04
HK1102760A1 (en) 2007-12-07
US8828397B2 (en) 2014-09-09
EP2377890B1 (en) 2016-08-10
US20090198044A1 (en) 2009-08-06
IL228033A0 (en) 2013-09-30
NZ578647A (en) 2012-04-27
SG187443A1 (en) 2013-02-28
UY28886A1 (es) 2005-12-30
JP2014094010A (ja) 2014-05-22
US20170190782A1 (en) 2017-07-06
EP1765396A4 (en) 2008-07-02
IL228032A0 (en) 2013-09-30
IL178838A (en) 2017-08-31
US10030075B2 (en) 2018-07-24
NO20065542L (no) 2007-01-31
RU2482131C2 (ru) 2013-05-20
JP2007536933A (ja) 2007-12-20

Similar Documents

Publication Publication Date Title
ECSP067056A (es) Anticuerpos
CR20140398A (es) Anticuerpos e inmunoconjugados anti-cd22
HN2006015949A (es) Anticuerpos de p-caderina
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
FR2882939B1 (fr) Dispositif de separation fluidique
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
TR201902882T4 (tr) Bir kontrol kanalı üzerinde kaynakların esnek sinyallenmesi.
HN2007006799A (es) Analogos de biaril piperazinil-piridina sustituidos
UY3723Q (es) Aerosol
ATE540027T1 (de) Tetrahydroindazol-cannabinoidmodulatoren
UY3565Q (es) Diseno de botella
ATE502093T1 (de) Klebstoffzusammensetzung auf polypropylenbasis
DK1888550T3 (da) Apoptosepromotorer
GT200700014S (es) Botella
DE602006003023D1 (de) Signalerzeugungsanlage für Fahrradsteuerungsvorrichtung
ITMI20050122U1 (it) Dispositivo antiabbagliamento per sorgenti luminose a led
AR064610A1 (es) Anticuerpos contra el cd200r
ECSP088691A (es) Procesos para la síntesis convergente de los derivados de caliqueamicina
DE602006002353D1 (de) Beleuchtete Folientastatur
ATE422497T1 (de) Nichtsteroide glucocorticoid-rezeptormodulatoren
NO20054838D0 (no) Dobbel-linje brikkekonstruksjon for lysmodulator
DE102006032267A1 (de) Optisches Interferometer
DE602008000475D1 (de) Schallquellentrennsystem
FR2922011B1 (fr) Instrument de secours pour aeronef.
ATE456119T1 (de) Tafelartiger plakathalter